Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EHC 2022
AES 2022
WSC 2022
ECTRIMS 2022
EHDN 2022
MDS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Multiple Sclerosis and Related Disorders
3:21
Emerging MS research: PIRA & prediction models
João José Cerqueira
• 28 Oct 2022
2:00
OCT measures association with serum/CSF biomarkers in CIS patients
Jaume Sastre-Garriga
• 28 Oct 2022
2:06
Challenges with stem cell therapy in MS
João José Cerqueira
• 28 Oct 2022
3:10
Biomarkers of disease activity and treatment response in MS
Mar Tintoré
• 4 Nov 2022
1:48
T-cell response following COVID-19 vaccination in MS patients under treatment
João José Cerqueira
• 28 Oct 2022
1:39
Addressing PIRA and PROMs in clinical practice
Mar Tintoré
• 4 Nov 2022
1:12
The value of including optic nerve lesions in MS diagnostic criteria
Angela Vidal-Jordana
• 26 Oct 2022
1:12
Autologous hematopoietic stem cell transplantation for the treatment of MS
Riccardo Saccardi
• 28 Oct 2022
1:37
Assisted reproductive technology treatment and the risk of MS
Melinda Magyari
• 28 Oct 2022
4:32
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS
João José Cerqueira
• 28 Oct 2022
1:08
Post-authorization safety study of teriflunomide in MS
Melinda Magyari
• 28 Oct 2022
1:36
Using high-efficacy treatments at initial stages of MS: addressing safety concerns
João José Cerqueira
• 28 Oct 2022
1:12
Imaging highlights in MS: updated guidelines, novel markers & remyelination
Celia Oreja-Guevara
• 28 Oct 2022
1:35
Relationship between UCC atrophy and brain metrics of disease activity in MS
Burcu Zeydan
• 27 Oct 2022
1:04
MDSA test classifies relapsing MS patients based on steroid response and disease activity status
Ferhan Qureshi
• 26 Oct 2022
1:16
Genetic contributions to MS severity to guide development of novel drugs
Adil Harroud
• 27 Oct 2022
Previous
1
2
3
4
5
6
7
…
37
Next